Cargando…
A patient with agranulocytosis following the discontinuation of methimazole treatment for 4 months: A case report
Agranulocytosis is a rare and serious adverse effect of antithyroid drugs (ATD), in particular methimazole (MMI), and usually develops within 3 months following the start of uninterrupted ATD treatment. Agranulocytosis may also develop for the first time following interruption and subsequent resumpt...
Autores principales: | BAI, XIAO-SU, LIU, JING-HAI, XIAO, SHAO-MEI |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4113532/ https://www.ncbi.nlm.nih.gov/pubmed/25120607 http://dx.doi.org/10.3892/etm.2014.1817 |
Ejemplares similares
-
Development of Agranulocytosis after Discontinuation of Methimazole: An Unusual Case
por: Üçler, Rıfkı, et al.
Publicado: (2015) -
Agranulocytosis with tonsillitis associated with methimazole therapy
por: Zambrana, Jorge T., et al.
Publicado: (2015) -
SAT-600 Relapse of Agranulocytosis after Recovery of Methimazole-Induced Agranulocytosis
por: Choi, Dughyun, et al.
Publicado: (2019) -
Two Cases of Methimazole-Induced Agranulocytosis With Their Risk Factors
por: Khine, Aye, et al.
Publicado: (2021) -
Use of granulocyte colony‐stimulating factor in the treatment of methimazole‐induced agranulocytosis: a case report
por: Birmingham, Asha, et al.
Publicado: (2017)